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Introduction
Goiter was first described between the years 2838-2698
B.C.E in the book Pen-Ts’ao Tsing (A Treatise on Herbs 
and Roots). The supposed author, emperor Shen-Nung, 
recommended the seaweed Sargassum as an effective 
remedy for goiter (1). It was not until the 1st century B.C.E.
that the writings of Roman authors Vitruvius, Pliny the Elder
and Juvenal, made reference to endemic goiter in a region of
the Alps. Although already recognized as a medical condition,
congenital hypothyroidism was not mentioned in medical
texts until year 1300 by Arnaldus de Villanova (goitres in 
Lucca) and Lanfrancus (goitres in Lombardy) (2). There have
been many advances in the study of congenital hypothyroidism
since then, most notably in the past forty years.
Normal thyroid function is essential for the growth and
neurodevelopment of infants and young children. Abnormalities
of thyroid gland development, migration and function can all
lead to congenital hypothyroidism. Recent reviews have 
included defects in the sodium-iodide transporter and 
the thyrotropin (TSH) receptor, as well as the transcription
factors (TFs) PAX-8, TTF1, TTF2 and others, all of which may
be associated with abnormalities in thyroid function.
The development of the normal fetal-neonatal thyroid
system can be categorized in three phases. The first one 
begins with thyroid and pituitary embryogenesis occurring
up to the 10th-12th weeks of gestation. The histologic 
and functional maturation of the hypothalamus and of the 
pituitary portal vascular systems begins at 4th-5th gestational
weeks and continues through gestational weeks 30-35. The
third and final phase of fetal thyroid development is the 
maturation of the hypothalamic-pituitary-thyroid axis beginning
at mid-gestation and continuing through to approximately 4
weeks postnatally. One can easily infer that infants born 
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of the fetal hypothalamic-pituitary-thyroid axis leading to 
abnormal thyroid function.   
Genetic defects in transcription factors have been 
described in relatively few patients. There is great variability
between genotype and phenotype in affected individuals.
For example, the same defect in PAX 8 may result in 
anywhere from a normal to an absent thyroid gland and from
euthyroidism to severe hypothyroidism (3,4,5,6,7,8) (Table 1).
Some of the TFs involved in thyroid gland development are
also involved in the development of other tissues, such as
the kidneys and lungs. There is an increased odds ratio 
of 13.2 for having renal and urinary tract abnormalities in 
children with congenital hypothyroidism versus children 
without congenital hypothyroidism (9). For further details 
of thyroid gland development, several reviews are 
recommended (10,11,12).
Thyroid function of the neonate can be affected by the
mother’s thyroid status by way of placental transfer. While
TSH is not transferred from the mother, small amounts of
thyroxine (T4) and triiodothyronine (T3) do cross the placental
barrier.  Thyroid antibodies, both stimulatory and inhibitory,
as well as anti-thyroid medication easily cross the placenta
and are transferred from the mother to the fetus. For
example, the thyroid stimulating immunoglobulins (TSI)
from a mother with Graves disease will cross the placental
barrier and can result in transient hyperthyroidism in 
the  neonate.  If this same mother is on treatment with 
thioamides, which also cross the placental barrier, the 
neonate can develop transient hypothyroidism. The possible
impact of the mother’s thyroid status could present a difficult
challenge to the physician in diagnosing thyroid abnormalities
in the neonate. We have recommended measurements of
TSI in such newborns as helpful in assessing the likelihood
of developing symptomatic hyperthyroidism (13).
Results of thyroid function tests (TFTs) vary with age.
There is a rise in TSH, T3 and T4 immediately after birth.
These measures of thyroid function will gradually decrease
by 3-4 days of age.  It is important to note that specimens
obtained on the first day of life might have a high TSH level
with high levels of T3 and T4. TFTs in babies born prior to
term need to be interpreted with careful regard for age and
gestational age. T4 and T3  are especially affected. TSH 
levels do not vary as greatly during the newborn period.  
If neonates with congenital hypothyroidism are 
left untreated, they will develop severe symptoms 
of hypothyroidism, such as developmental and growth 
retardation.  In order to avoid potential damage to the 
developing brain caused by congenital hypothyroidism,
newborn screening was instituted in Quebec, Canada in
1974. The frequency of congenital hypothyroidism was 
found to be 1:7000 and the screening program was 
continued (14). With the expansion of newborn screening
programs, the frequency of congenital hypothyroidism 
continues to increase in the United States (US) and 
worldwide and is now thought to be around 1:3000-4000.
In New York State alone, between 1978 and 2005, the 
incidence of  congenital hypothyroidism has increased by
138% to approximately 1:1415 births. In the US (excluding
New York State data), with nearly 58 million infants 
screened between 1987 and 2002, the incidence has
increased 73% (15). The largest proportion of newborn
screening programs worldwide and in the US use a primary
T4 screen with TSH measured to confirm the lowest T4
results. Other countries and fewer US states use a primary
TSH screen alone. In the US, a limited number of states
perform both a primary T4 and TSH screen at the 
initial screening (16,17). 
It is important to note that two-thirds of infants diagnosed
with congenital hypothyroidism had neither signs nor 
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Table 1. Genetic mutations and variant phenotypes
Variation Phenotype Function Reference
PAX8:
T225M Normal size Euthyroid Tonacchera et al (4)
Ectopia Mild hypothyroidism
Hypoplasia Severe hypothyroidism
TTF-1:
Whole gene deletion Normal size Mild hypothyroidism Iwatani et al (5)
Hypoplasia Severe hypothyroidism Krude et al (6)
TTF-2/FOXE1
Missense mutations Athyreosis Hypothyroidism Castanet et al (7)
Hypoplasia Severe hypothyroidism Baris et al (8)symptoms of hypothyroidism. Transient hypothyroxinemia
is common in neonates born prematurely. Thyroxine-binding
globulin (TBG) deficiencies occur in 1:9000, while TSH
and/or TRH deficiencies occur in less than 1:20000-100000.
A study in the Netherlands that screened 385000 infants
over a two-year period found that congenital hypothyroidism
of central origin occurs more often than previously thought.
They reported an incidence of 1:20000, representing 13.5%
of all cases of permanent congenital hypothyroidism. Over
three quarters of the permanent cases of congenital central
hypothyroidism had multiple pituitary hormone 
deficiency and half had pituitary malformations (18).
Treatment for congenital hypothyroidism is thyroid 
hormone replacement. The current recommended dose is
10-15 μg/kg/day of thyroxine, to be given orally as crushed
tablets.  Treatment should be instituted as early as possible,
in order to optimize cognitive and physical development.
Most children do well with treatment, and higher initial
thyroxine dosage combined with shorter time to normalization
contribute to improved developmental outcome (19,20).
Some suggest that the dose of thyroid hormone required
may be directly related to the etiology of the hypothyroidism.
Infants with athyreosis require a higher dose than those
with dysgenesis, who require a higher dose than those 
with dyshormonogenesis (21). Contrary to previous beliefs,
congenital hypothyroidism, even due to thyroid dysgenesis,
may not be a random occurrence. In a 2001 review of 19 
years of newborn screening in France, Castanet et al (22)
found that familial cases were reported in a high proportion
of children with thyroid dysgenesis, suggesting the possibility
of a genetic component. A further review in 2010 by Castanet
et al (23) estimates the prevalence of familial cases of
thyroid dysgenesis at 2%.
Treatment with thyroid hormone has generally been 
quite safe and effective. In young adults diagnosed through
the national neonatal screening program in the Netherlands,
it was found that in neonates with severe congenital
hypothyroidism,cognitive and motor defects persist 
through young adult life. The median age of start of treatment
was 28 days after birth and was not an important factor in
determining long-term cognitive and motor outcome. The
study concludes that the severity of congenital hypothyroidism
is inversely correlated with IQ and motor scores (24). 
Impaired diastolic function and exercise capacity in 
young adults treated with levothyroxine for congenital
hypothyroidism has also been reported. Compared with
controls, hypothyroid patients exhibited a higher frequency
of left ventricular diastolic dysfunction, impaired exercise
capacity, and increased intima-media thickness. Close 
monitoring of thyroid hormone replacement therapy can
prevent cardiovascular abnormalities related to episodes of
subclinical hypothyroidism and hyperthyroidism (25).
In neonates with an initial abnormal screen accompanied
by normal serum T3 and T4 levels and only mildly elevated
TSH, one is faced with a conundrum of mild abnormalities.
Based on a 1993 study, we recommended thyroid releasing
hormone (TRH) testing for children who had mildly elevated
baseline TSH values in order to identify those infants in
whom thyroid hormone replacement may be needed, even
if transiently (26). This approach was substantiated in an 
article by Daliva et al (27) who showed that 13 of 14 children
with borderline TSH levels at screening had thyroid 
function anomalies that persisted at three years of age. Of
those 13 children, three underwent TRH testing, with two
exhibiting hyper-responsiveness (>35mU/L) (27,28). Recent
studies have shown that certain genetic defects can result in
either mild or transient hypothyroidism (29,30,31) (Table 2).
Therefore, TRH testing should be recommended to identify
cases of mild congenital hypothyroidism. In addition, TRH
testing has a role in diagnosing central hypothyroidism and 
isolated TSH deficiency (32). 
A common finding in preterm newborns is neonatal
hypothyroxinemia. Neonatal hypothyroxinemia has been 
associated  with cerebral palsy, mortality, morbidity, and 
intraventricular hemorrhage (33,34). Attempts have been 
made to replace T4 in premature infants with limited 
demonstrable results (35,36,37). In 2001, we recommended
that hypothyroxinemia of the preterm infant should not be 
routinely treated in Neonatal Intensive Care Units, unless
aspart of an ongoing study (38). In 2007, a Chochrane 
Database Systematic Review also did not support the use of
prophylactic thyroid hormones in preterm infants to 
reduce neonatal mortality, neonatal morbidity or improve 
neurodevelopmental outcomes (39). Prospective studies of
thyroid hormone supplementation in premature neonates are
underway (40).
Late rise in TSH (LRT) is defined as an elevated TSH 
level following a normal TSH on the initial newborn screen,
with either a normal or a low T4.  LRT can occur in premature
or ill infants and babies with very low birth weight.  We have
recommended routine monitoring of TFTs in ill newborns
(41). Possible causes of LRT are developmental delays in
the maturation of the hypothalamic-pituitary-thyroid axis,
exposure to medications and antiseptics, and recovery from
sick euthyroid syndrome. A one-year study found 14 infants
who had late rise in TSH.  Nearly half the cases (n=6) 
resolved spontaneously, while the remaining 8 infants 
required thyroid hormone replacement. Of these 14 infants,
79% were premature and 7 had very low birth weight
(VLBW). Ten of these infants underwent surgery and 
of those, 6 had elevated urine iodine. We concluded that
LRT in ill newborns may be a common finding and not 
necessarily associated with birth weight (42).
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newborns.  Particular attention should be paid to recognizing
specific disorders of the thyroid gland.  It is imperative that
any thyroid function abnormalities be identified and treated
as early as possible to ensure the best neurodevelopmental
and growth outcomes. Genetic studies have already helped
to identify the etiology of congenital hypothyroidism in 
some infants. Expanded genetic screening is likely to be
more available in the near future.  
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